Our Weight Loss Pill Treatment Options
Clinically proven weight management, in a once-daily tablet
Whatever stage you’re at, the support around you stays the same. One clinical team. One programme. One daily tablet.
Wegovy weight loss pill available early July
Join our waitlist to be first to hear release dates.
The Wegovy Pill is a once-daily oral weight loss tablet containing semaglutide, the same active ingredient as the Wegovy injection, now in tablet form. It will be the first oral GLP-1 weight loss pill available in the UK, coming to CheqUp from July 2026.
Further information and news is expected in the coming weeks. Sign up to our Oral GLP-1 medication waitlist below.
Sign up to join our weight loss pill waitlist
Enter your first name and email address below and we’ll keep you updated on the latest news, release dates and more surrounding weight loss tablets.
By signing up, you agree to receive marketing messages via email from CheqUp Health. You can unsubscribe at any time by following the unsubscribe link at the bottom of any marketing email we send.
Less daunting. Same results.
No injections
One tablet, first thing each morning. No needles, no weekly pen — just a simple routine that fits around your day.
Around 16.6% average weight loss
In the OASIS 4 trial, people lost an average of 16.6% of body weight over 64 weeks — broadly in line with the standard injection.¹
Full clinical support included
Your Clinician, Health Coach and Weight Watchers app come with every CheqUp membership — however you choose to treat.
¹ OASIS 4 trial, oral semaglutide 25mg over 64 weeks.
How effective is the Wegovy pill?
In a 64-week clinical trial, OASIS 4 (307 adults living with obesity or overweight with at least one weight-related condition), participants taking oral semaglutide 25mg alongside lifestyle support lost an average of 16.6% of their body weight, versus 2.2% with placebo.¹
Based on the OASIS 4 Phase 3 trial, conducted alongside a lifestyle intervention. Results represent estimated outcomes assuming 100% adherence in a clinical trial population. Individual results will vary. As with all weight loss treatments, individual results varied.
¹ https://www.nejm.org/doi/full/10.1056/NEJMoa2500969
| Weight loss achieved | Semaglutide (25mg) | Placebo |
|---|---|---|
| ≥5% body weight loss | 76% | 31% |
| ≥10% body weight loss | 60% | 14% |
| ≥15% body weight loss | 47% | 6% |
| ≥20% body weight loss | 28% | 3% |
See how much you could lose
Based on average results from the OASIS 4 clinical trial.
Starting weight
With the Wegovy pill you could lose:
over 64 weeks
Individual results may vary. Based on OASIS 4 trial data. Results assume 100% adherence.
Join the waitlistHow do weight loss tablets work compared to injections?
Same ingredients, different method
Both pills work through the same clinical pathway as injectable treatments, reducing appetite and slowing digestion. The Wegovy pill showed around 16.6% average weight loss at its highest dose. Orforglipron showed around 12.4%. Clinically meaningful results, without a needle.
*Individual results may vary.*
No needles, no injection sites
Injectable treatments are self-administered once a week, into the abdomen, thigh, or upper arm. Both pills are swallowed once daily. No injection pen to load, no needle, no rotating injection sites. For anyone who found the injection a barrier, this changes things.
No fridge. No weekly schedule.
Both pills are stored at room temperature and taken daily. No injection pen, no refrigeration, no planning around a weekly dose. Easier to travel with, easier to fit into everyday life.
Which weight loss tablets will be available and how do they compare?
The Wegovy Pill (Semaglutide)
Developed by Novo Nordisk, the company behind the injectable Wegovy treatments. Available July 2026
The Wegovy Pill contains the same active ingredient as the Wegovy injection – semaglutide – which works by reducing appetite and supporting long-term weight loss. In clinical trials it showed around 16.6% average weight loss at the highest dose. Individual results may vary.
It is taken once daily, first thing in the morning on an empty stomach with up to 120ml of plain water. You must wait 30 minutes before eating, drinking, or taking other medication, to ensure it is absorbed properly.
Orforglipron (UK brand name to be confirmed)
Developed by Eli Lilly, the company behind the Mounjaro treatments
Orforglipron works in the same way as the Wegovy pill, reducing appetite and supporting long-term weight loss. In clinical trials it showed around 12.4% average weight loss at the highest dose, with particularly strong evidence for maintaining weight loss over time. Individual results may vary.
Unlike the Wegovy pill, it can be taken at any time of day, with or without food or drink, with no waiting period required.
How do weight loss tablets actually work?
Mimics GLP-1
It imitates the glucagon-like peptide-1 (GLP-1) hormone, which is what your body normally releases after eating, to stop food cravings.
Slows digestion
It slows down how quickly your stomach empties, keeping you feeling full and satisfied for much longer after smaller meals.
Regulates Blood Sugar
It stimulates insulin secretion when blood sugar is high, which helps stabilise energy levels and further reduces cravings.
Looking to start weight loss medication?
Struggled with weight for years? You’re not alone
From busy careers and family life to navigating menopause and midlife health, many have found lasting weight loss with CheqUp
86% of CheqUp’s members feel confident in their ability to maintain their weight long term.*
*Based on a customer survey, 2831 respondents, December 2025
Oral weight health medications: what you need to know
Everything you need to know about the latest weight loss tablet options, how they work and how they compare.
Wegovy Pill vs Wegovy injection: what’s the difference?
With the Wegovy tablet set to launch in the UK, many people are wondering how it compares to the injectable…
What is the new weight loss pill?
Two new weight loss pills are coming to the UK - the Wegovy pill and orforglipron - and for many…
How to switch from injectable GLP-1s to pills
Thinking about switching from Wegovy or Mounjaro injections to a weight loss pill? Two new oral treatments are coming to…
What is orforglipron?
Orforglipron is a new once-daily weight loss tablet developed by Eli Lilly, currently under review by the MHRA and expected…
Switching to the Wegovy Pill: 10 things to know before you make the move
If you are currently on an injectable GLP-1 treatment and thinking about switching to the Wegovy Pill, here is what…
Frequently asked questions
You can read all of our FAQs here
How can I switch from injectable GLP-1s to tablets?
Switching from injectable GLP-1 medications to oral weight loss tablets may be an option for people looking for a more convenient, needle-free treatment. However, changing medication should always be done under clinical supervision. A healthcare professional will typically review your current treatment progress, side effects, medical history and weight loss goals before recommending a switch.
What is Orforglipron?
Orforglipron is a new oral GLP-1 medication being developed to support weight loss and type 2 diabetes treatment. Unlike injectable GLP-1 medications such as Wegovy and Mounjaro, orforglipron is taken as a once-daily tablet. It works by helping regulate appetite, reduce cravings and lower calorie intake, supporting sustainable weight loss over time.
Early clinical trial results have shown promising weight loss outcomes, making orforglipron one of the most anticipated upcoming alternatives to injectable weight loss medication.
How can I start taking weight loss medication pills?
Starting weight loss medication pills begins with a clinical assessment to determine whether treatment is suitable for you. A healthcare provider will typically review your BMI, medical history, current health conditions and weight loss goals before recommending the most appropriate medication.
How effective are weight loss pills compared to injectables?
New oral GLP-1 weight loss pills, including oral semaglutide and orforglipron, have also shown strong results in clinical trials. Some studies suggest oral GLP-1 tablets may achieve weight loss results close to injectable treatments when taken consistently, with reported average reductions ranging from around 10% to 16% depending on the medication and dosage.
Over 13,500 verified customer reviews
*Based on a customer survey, 2831 respondents, December 2025